A Study to Assess the Gut Health Effects of Heat-killed Post-biotics in Overweight and Obese Adults
NCT ID: NCT05820737
Last Updated: 2025-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
155 participants
INTERVENTIONAL
2024-04-14
2025-03-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of a Probiotic on Visceral Fat Accumulation
NCT02921217
Effects of the Bifidobacterium Longum BL21 on BMI, Metabolic Indicators, and Gut Microbiota in Overweight/Obese Adults
NCT06140641
Effect of Bifidobacterium Breve B-3 on Body Fat in Obese Adults
NCT03774381
Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals
NCT05428137
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
NCT03759743
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
1 capsule to be consumed once a day
Placebo
One capsule to be consumed once a day
EF2001
1 capsule to be consumed once a day
EF2001
One capsule to be consumed once a day
beLP1
1 capsule to be consumed once a day
beLP1
One capsule to be consumed once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EF2001
One capsule to be consumed once a day
beLP1
One capsule to be consumed once a day
Placebo
One capsule to be consumed once a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI of ≥ 25 - ≤ 35 kg/m2
* Individuals with liver \& renal function test values as defined below:
1. Individuals with ALT, AST values ≤ 2 times of the upper limit of normal (ULN).
2. Individuals with creatinine values ≤ 1.5 times of the upper limit of normal (ULN).
3. Individuals with ALP values ≥ 38 and ≤ 126 U/L
* Having at least two of the following five metabolic risk factors:
1. Waist circumference \> 102 cm (40 inches) for men and \> 88 cm (35 inches) for women
2. Fasting triglycerides \>150 mg/dL and \< 300 mg/dl
3. Blood pressure ≥130 mm Hg (Systolic Blood Pressure) and/or ≥85 mm Hg (Diastolic Blood Pressure)
4. Fasting blood glucose ≥ 100 mg/ dl
5. Fasting HDL cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women)
* History of mild to moderate gastrointestinal discomfort for at least last three months
* Individuals experiencing moderate-intensity gastrointestinal symptoms, evaluated based on the combined scores of two GSRS domains (dyspeptic syndrome and bowel dysfunction), falling within the range of ≥ 15 and ≤ 29 over the past two weeks. (The highest score out of two weeks' GSRS scores will be taken into consideration for the study)
* Willing to complete all study procedures including study-related questionnaires and comply with study requirements.
* Willing to abstain from other supplements or medication.
* Ready to give voluntary, written, informed consent to participate in the study
* No prohibited antibiotic usage within the last 30 days.
* History of stable weight over the last 6 months (\<10% change)
* Willing to maintain current dietary and exercise habits, aside from any changes to be made per the study exercise protocol
Randomization Criteria:
* Two weeks of run - in period for weight stability (Weight instability defined as \> 2 kg of weight gain or loss over 2 weeks of run-in period)
* GSRS scores not less than that reported at screening. (The highest score out of two weeks' GSRS scores will be taken into consideration for the study)
* Both the weekly at-home diaries for GSRS should be available
* 80% compliance to the run-in medication
Exclusion Criteria
* Presence of unstable, acutely symptomatic, or life-limiting illness.
* Individuals diagnosed with diabetes and are on active medication
* FBG \> 125 mg/dl
* Individuals diagnosed with hypertension and are on active medication.
* Individuals with uncontrolled hypertension with systolic blood pressure ≥150 and/or diastolic blood pressure ≥100 mm Hg.
* Individuals with neurological conditions causing functional or cognitive impairments.
* Individuals with a history or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders that, in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the subject at undue risk.
* Individuals under use of any psychotropic medication within four weeks of screening and throughout the study
* Individual under use of antibiotics or signs of active systemic infection at the time of screening. Treatment visits will be rescheduled to allow the subject to wash off the antibiotic for at least five days prior to any test visit
* Individual states they regularly consume supplemental enzymes and are unwilling to stop at least one week prior to screening and throughout the study. Supplemental enzymes may include standalone enzyme supplements, probiotic supplements with enzymes, and any medications containing enzymes.
* Individuals states they regularly consume probiotic supplements and are unwilling to stop at least one week prior to screening and throughout the study. Supplemental probiotics may include standalone probiotic supplements, vitamins with probiotics, and any foods supplemented with probiotics
* Exposure to any non-registered drug product within 3 months prior to the screening visit.
* Unable/unwillingness to complete study specific diaries (digital/paper-based).
* Current use of the following medications: monoamine oxidase inhibitors, prescription or herbal weight loss medications/ dietary supplement.
* Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
* Individual who reports alcohol intake as average of 3 or more servings per day 18. Individuals with thyroid dysfunction as assessed by TSH ≤ 0.4 or ≥ 4.3 mIU/L.
* Individuals state they have an allergy or intolerance to any ingredient in the study product or test meal.
* Individual is deemed unsuitable for study based upon study physician assessment.
* Individual is taking part in another clinical trial
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. KotharisDigestive andLiver care
Pune, Maharashta, India
AIIMS Hospital
Dombivali, Maharashtra, India
Ramesh Dargad Clinic
Mumbai, Maharashtra, India
Sarthak Health Clinic.
Nashik, Maharashtra, India
Surya Multispeciality hospita
Nashik, Maharashtra, India
Dr. Thakare superspeaciality clinic
Nashik, Maharashtra, India
Life care Hospital
Nashik, Maharashtra, India
Metabol
Ghātkopar, , India
Dhanwantari Hospita
Pune, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR/221101/EFLP/GH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.